TICKERNERD
Menu
XTNTXTNTHealthcare · Medical Devices

XTNT Stock Forecast: Xtant Medical Holdings, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$0.35
+1.71% on the day

The 3 Wall Street analysts covering Xtant Medical Holdings, Inc. hold a median 12-month price target of $1 — +189.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 11 Sept 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$48.5M
Ticker Nerd rank
72 / 100
Median analyst target
$1.00
Analysts covering
3
Revenue$23.0M−35.0% y/y
Operating income−$4.2M
Net income−$9.4M
Free cash flow−$7.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.6%
1M
+8.1%
YTD
−55.7%
1Y
−44.2%
From 52W high
−62.4%
From 52W low
+11.5%
$0.31
$0.92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XTNT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xtant Medical Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
72 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
96
Issuance
84
Size
82
Quality
74
Value
64
Volatility
63
Momentum
38
Revisions
36
Growth
20

Accruals (96): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (20): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

XTNT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XTNT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.20$0.40$0.60$0.80$1.00$1.20$1.40$1.60Oct 25Jan 26Apr 26Jul 26XTNTHigh $1.50Median $1.00Low $0.60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $0.60Median $1.00High $1.50

The green dot is the last close — the median target sits +189.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Sept 2026LUCID CAPITAL MARKETSInitiatesBuy—
13 May 2026BTIGReiteratesBuy—
31 Mar 2026BTIGMaintainsBuy—
11 Nov 2025BTIGMaintainsBuy—
16 May 2024BTIGMaintainsBuy—
5 Dec 2023BTIGInitiatesBuy—
11 July 2023Craig-HallumMaintainsBuy—
26 Apr 2023Craig-HallumInitiatesBuy—
17 May 2019Maxim GroupDowngradeHold—
8 Dec 2016Maxim GroupInitiatesBuy—
30 Nov 2016Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XTNT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

XTNT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Xtant Medical Holdings, Inc. returned −44.2% against +17.5% for the S&P 500, dividends included.

XTNT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Oct 25Jan 26Apr 26Jul 26XTNTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XTNT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Xtant Medical Holdings, Inc. (XTNT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
32.0×

Cheaper than 24% of US stocks

Price / sales
0.4×

Cheaper than 84% of US stocks

Price / book
1.2×

Cheaper than 67% of US stocks

EV / EBITDA
−43.7×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
−35.0%

Higher than 8% of US stocks

Earnings growth (YoY)
−35.0%

Higher than 14% of US stocks

Gross margin
57.9%

Higher than 71% of US stocks

Operating margin
−18.1%

Higher than 22% of US stocks

Net margin
−10.2%

Higher than 20% of US stocks

Returns & dividend
Return on equity
−25.2%

Higher than 29% of US stocks

Return on assets
−3.8%

Higher than 33% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Xtant Medical Holdings, Inc. (XTNT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xtant Medical Holdings, Inc. has a market value of $48.5M and an enterprise value of $64.4M.

  • Revenue in the twelve months to 30 June 2026: $109.5M. The latest quarter shrank 35.0% year on year.

  • Net income over the same four quarters: −$11.1M, a −10.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.08.

  • Free cash flow in the twelve months to 30 June 2026: −$696K.

  • Shares outstanding: 140.3M.

  • Trailing P/E: 32.0×; forward P/E: −11.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Xtant Medical Holdings, Inc. employs 151 people — $725K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

XTNT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
XTNTXtant Medical Holdings, Inc.$48.5M
72
MDAISpectral AI, Inc.$49.1M
15
BDMDBaird Medical Investment Holdings Ltd.$46.4M
19
MYOMyomo, Inc.$51.5M
53
SRTSSensus Healthcare, Inc.$51.8M
51
TELATELA Bio, Inc.$43.2M
31
NNOXNano-X Imaging Ltd.$56.9M
19

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xtant Medical Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XTNT news & analysis

Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market

PRNewsWire · 27 Aug 2026positive

Xtant Medical announced an exclusive partnership with BioHorizons, a Henry Schein company, under which BioHorizons will distribute Xtant's allogeneic growth factor technology, OsteoFactor Pro, private branded as Prolifica, through its commercial network to expand access into the dental market.

Why it matters — This expands the distribution of Xtant's allogeneic growth factor technology into the dental market through BioHorizons' established commercial network.

Xtant Medical Holdings, Inc. (XTNT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

Xtant Medical Holdings held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha.

Why it matters — XTNT watchers would want to review the earnings call transcript for details on the company's financial performance and strategic outlook for the quarter.

Xtant Medical Reports Second Quarter 2026 Financial Results

PRNewsWire · 11 Aug 2026neutral

Xtant Medical Holdings reported its financial and operating results for the second quarter ended June 30, 2026. The company also announced the launch of Trivium™ Shaped, an extension of its Trivium line of demineralized bone matrix allografts, and will host an investor conference call on August 11 at 8:30am ET.

Why it matters — XTNT watchers would care because the quarterly results and the new product launch provide an update on the company's recent financial performance and its product portfolio expansion.

Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026

PRNewsWire · 6 Aug 2026neutral

Xtant Medical announced it will release its second quarter 2026 financial results before trading opens on August 11, 2026. The results cover the period ended June 30, 2026.

Why it matters — The release will provide investors and analysts with an update on Xtant's financial performance and operational results for the recent quarter.

Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference

PRNewsWire · 4 Aug 2026neutral

Xtant Medical announced that CEO Sean Browne, CFO Scott Neils, and COO Mark Schallenberger will participate in the Canaccord Genuity 46th Annual Growth Conference, held August 11-13, 2026, in Boston. The company is a medical technology firm focused on surgical solutions for spinal and other orthopedic conditions.

Why it matters — Xtant's management will present the company to investors and industry participants at a major growth conference, offering potential visibility for the company.

FAQ

Frequently asked questions about XTNT stock

What is the XTNT stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Xtant Medical Holdings, Inc. have a median 12-month price target of $1, with estimates ranging from $0.6 to $1.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is XTNT stock a buy right now?

Of the 3 analysts covering Xtant Medical Holdings, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xtant Medical Holdings, Inc. 72 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XTNT?

As at 11 Sept 2026, Xtant Medical Holdings, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (96 of 100).

Will XTNT stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +189.2% from the last close, and Ticker Nerd's factor model ranks Xtant Medical Holdings, Inc. 72 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the XTNT stock forecast for 2030?

No analyst covering Xtant Medical Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XTNT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $0.6 to $1.5 over the next 12 months.

How has XTNT stock performed over the past year?

Xtant Medical Holdings, Inc. returned -44.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xtant Medical Holdings, Inc. do?

Xtant Medical Holdings, Inc. is a medical technology company that develops, manufactures, and markets regenerative medicine products and spinal implant systems for orthopedic and neurological surgeons.

What is the latest news on XTNT?

The most recent item we track (PRNewsWire, 27 Aug 2026): "Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market". Xtant Medical announced an exclusive partnership with BioHorizons, a Henry Schein company, under which BioHorizons will distribute Xtant's allogeneic growth factor technology, OsteoFactor Pro, private branded as Prolifica, through its commercial network to expand access into the dental market.

Company

About Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. is a medical technology company that develops, manufactures, and markets regenerative medicine products and spinal implant systems for orthopedic and neurological surgeons. Its product portfolio includes orthobiologics, bone graft substitutes, biologic scaffolds, tissue-based products, and spinal fixation devices used in procedures involving spinal fusion, bone healing, and the treatment of complex spine and orthopedic conditions. The company also serves related surgical areas such as chronic wound care, sports medicine, cranial repair, and foot and ankle applications. Xtant Medical Holdings, Inc. focuses on products that support surgical reconstruction and biologic healing across domestic and international markets. Based in Belgrade, Montana, the company operates as a specialized supplier within the medical device and regenerative medicine sectors.

CEO Mr. Sean E. Browne · 151 employees · United States · https://xtantmedical.com